Fibrosis in Chronic and Delayed Myocardial Infarction

Who May Qualify: Cohort 1(Aortic stenosis): - Male or female above the age of 50 years old - Provision of willing to sign a consent form prior to any study specific procedures - 25 patients with symptomatic severe aortic stenosis (peak velocity \>4.0 m/s) - 25 patients with moderate aortic stenosis (peak velocity 3.0-4.0 m/s) - 10 patients with mild aortic stenosis (peak velocity 2.6-2.9 m/s) - 10 patients with aortic sclerosis (tri-leaflet thickened aortic valve with no obstruction of ventricular outflow) - 10 healthy volunteers (no other significant co-morbidities, as assessed by the study PI) Cohort 2 (Chemotherapy-induced cardiotoxicity): - Male or female over the age of 35 years with evidence of cardiotoxicity on cardiac MRI (performed as part of the Cardiac care study), at least 1 year after anthracycline treatment. - 10 patients over the age of 35 years (male or females) without evidence of fibrosis on their 1-year scan after anthracycline treatment. - 10 healthy volunteers (\>35 years of age) with no significant co-morbidities, as assessed by the study PI. - Provision of willing to sign a consent form prior to any study specific procedures Cohort 3 (Carcinoid syndrome): - 30 patients with carcinoid syndrome (with or without cardiac involvement), over the age of 35 years, diagnosed as per consensus guidelines - Provision of willing to sign a consent form prior to any study specific procedures Who Should NOT Join This Trial: - Inability or unwilling to give willing to sign a consent form. - History of claustrophobia or feeling of inability to tolerate supine position for the MRI scans. - Impaired renal function with eGFR of \<30 mL/min/1.73m2. - Women who are pregnant or breastfeeding. - Contrast allergy - Contraindication to cardiac MRI (e.g. metallic implant or severe claustrophobia) - Recent myocardial infarction, other known causes of cardiomyopathy/cardiac fibrosis. Always talk to your doctor about whether this trial is right for you.